25 November 2024
EMA/PRAC/520862/2024
Human Medicines Division

Pharmacovigilance Risk Assessment Committee (PRAC)

Draft agenda for the meeting on 25-28 November 2024

Chair: Ulla Wändel Liminga – Vice-Chair: Liana Martirosyan

25 November 2024, 13:00 – 19:30, room 1C

26 November 2024, 08:30 – 19:30, room 1C

27 November 2024, 08:30 – 19:30, room 1C

28 November 2024, 08:30 – 16:00, room 1C

Organisational, regulatory and methodological matters (ORGAM)

14 November 2024, 09:00 – 12:00, via teleconference

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised.

Of note, this agenda is a working document primarily designed for PRAC members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006 Rev.1).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the PRAC plenary session to be held 25-28 November 2024. See December 2024 PRAC minutes (to be published post January 2025 PRAC meeting).

1.2. Agenda of the meeting on 25-28 November 2024

Action: For adoption

1.3. Minutes of the previous meeting on 28-31 October 2024

Action: For adoption

2. EU referral procedures for safety reasons: urgent EU procedures

2.1. Newly triggered procedures

None

2.2. Ongoing procedures

None

2.3. Procedures for finalisation

None

3. EU referral procedures for safety reasons: other EU referral procedures

3.1. Newly triggered procedures

None

3.2. Ongoing procedures

None

3.3. Procedures for finalisation

None

3.4. Re-examination procedures[1]

None

3.5. Others

None

4. Signals assessment and prioritisation[2]

4.1. New signals detected from EU spontaneous reporting systems and/or other sources

4.1.1. Adalimumab – AMGEVITA (CAP); AMSPARITY (CAP); HEFIYA (CAP); HUKYNDRA (CAP); HULIO (CAP); HUMIRA (CAP); HYRIMOZ (CAP); IDACIO (CAP); IMRALDI (CAP); LIBMYRIS (CAP); YUFLYMA (CAP)

Applicants: AbbVie Deutschland GmbH & Co. KG (Humira), Amgen Europe B.V. (Amgevita), Biosimilar Collaborations Ireland (Hulio), Celltrion Healthcare Hungary Kft. (Yuflyma), Pfizer Europe MA EEIG (Amsparity), Fresenius Kabi Deutschland GmbH (Idacio), Samsung Bioepis NL B.V. (Imraldi), Sandoz GmbH (Hefiya, Hyrimoz), STADA Arzneimittel AG (Hukyndra, Libmyris)

PRAC Rapporteur: Karin Bolin

Scope: Signal of paradoxical hidradenitis

Action: For adoption of PRAC recommendation

EPITT 20126 – New signal

Lead Member State(s): SE

4.1.2. Emtricitabine, tenofovir disoproxil – EMTRICITABINE/TENOFOVIR DISOPROXIL KRKA, EMTRICITABINE/TENOFOVIR DISOPROXIL KRKA D.D., EMTRICITABINE/TENOFOVIR DISOPROXIL MYLAN, EMTRICITABINE/TENOFOVIR DISOPROXIL ZENTIVA, TRUVADA (CAP), NAP

Applicant(s): Gilead Sciences Ireland UC (Truvada, Emtricitabine/Tenofovir disoproxil Mylan), KRKA, d.d., Novo mesto (Emtricitabine/Tenofovir disoproxil Krka, Emtricitabine/tenofovir disoproxil Krka d.d.), Zentiva k.s. (Emtricitabine/Tenofovir disoproxil Zentiva), various

[1] Re-examination of PRAC recommendation under Article 32 of Directive 2001/83/EC
[2] Each signal refers to a substance or therapeutic class. The route of marketing authorisation is indicated in brackets (CAP for Centrally Authorised Products; NAP for Nationally Authorised Products including products authorised via Mutual Recognition Procedures and Decentralised Procedure). Product names are listed for reference Centrally Authorised Products (CAP) only. PRAC recommendations will specify the products concerned in case of any regulatory action required

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Signal of trigeminal neuralgia

Action: For adoption of PRAC recommendation

EPITT 20121 – New signal

Lead Member State(s): PT

4.1.3. Regorafenib – STIVARGA (CAP)

Applicant: Bayer AG

PRAC Rapporteur: Bianca Mulder

Scope: Signal of nephrotic syndrome

Action: For adoption of PRAC recommendation

EPITT 20123 – New signal

Lead Member State(s): NL

4.2. Signals follow-up and prioritisation

4.2.1. Azathioprine - JAYEMPI (CAP), NAP - EMEA/H/C/005055/SDA/003

Applicant(s): Lipomed GmbH, various

PRAC Rapporteur: Karin Erneholm

Scope: Signal of non-cirrhotic portal hypertension/portosinusoidal vascular disease

Action: For adoption of PRAC recommendation

EPITT 20091 – Follow-up to July 2024

4.2.2. Doxycycline (NAP)

Applicant(s): various

PRAC Rapporteur: Liana Martirosyan

Scope: Signal of suicidality; Third party intervention

Action: For adoption of PRAC recommendation

EPITT 19997 – Follow up to April 2024

4.2.3. Nitric oxide - INOMAX (CAP), NAP - EMEA/H/C/000337/SDA/026

Applicant(s): Linde Healthcare AB, various

PRAC Rapporteur: Jo Robays

Scope: Signal of pulmonary oedema in patients with veno-occlusive disease

Action: For adoption of PRAC recommendation

EPITT 20086 – Follow-up to July 2024

4.2.4. Risperidone[3] (NAP)

Applicant(s): various

PRAC Rapporteur: Martin Huber

Scope: Signal of medication errors associated with accidental overdoses in children and adolescents treated with risperidone 1 mg/mL oral solution

Action: For adoption of PRAC recommendation

EPITT 20085 – Follow-up to July 2024

Lead Member State(s): DE

4.2.5. Rosuvastatin (NAP)

Applicant(s): various

PRAC Rapporteur: Bianca Mulder

Scope: Signal of tubulointerstitial nephritis

Action: For adoption of PRAC recommendation

EPITT 20084 – Follow-up to July 2024

4.3. Variation procedure(s) resulting from signal evaluation

4.3.1. Anakinra - KINERET (CAP) - EMEA/H/C/000363/II/0093

Applicant: Swedish Orphan Biovitrum AB (publ)

PRAC Rapporteur: Karin Erneholm

Scope: Update of section 4.4 of the SmPC in order to add a new warning on 'Amyloidosis (systemic)' based on an updated safety review, following the PRAC recommendation on a signal. In addition, the MAH took the opportunity to correct a numerical error in the SmPC

Action: For adoption of PRAC Assessment Report

5. Risk management plans (RMPs)

5.1. Medicines in the pre-authorisation phase

5.1.1. Atropine (CAP MAA) - EMEA/H/C/006324

Scope (pre D-180 phase): Treatment of progression of myopia in children aged 3 to 18

[3] Oral solution only

years

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.2. Belzutifan (CAP MAA) - EMEA/H/C/005636

Scope (pre D-210 phase): Treatment of adult patients with advanced renal cell carcinoma (RCC) and treatment of adult patients with von Hippel-Lindau (VHL) disease

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.3. Eltrombopag (CAP MAA) - EMEA/H/C/006459

Scope (pre D-180 phase): Treatment of primary immune thrombocytopenia (ITP), chronic hepatitis C virus (HCV) and acquired severe aplastic anaemia (SAA)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.4. Govorestat - EMEA/H/C/006270, Orphan

Applicant: Advanz Pharma Limited

Scope (pre D-180 phase): Treatment of adults and children aged 2 years and older with a confirmed diagnosis of classic galactosemia

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.5. Human normal immunoglobulin (CAP MAA) - EMEA/H/C/006423

Scope (pre D-180 phase): Replacement therapy (primary immunodeficiency syndromes and secondary hypogammaglobulinemia), immunomodulation (in primary immune thrombocytopenic purpura, Guillain Barré syndrome, Kawasaki disease and Multifocal Motor Neuropathy)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.6. Lifileucel (CAP MAA) - EMEA/H/C/004741

Scope (pre D-120 phase): Treatment of unresectable or metastatic melanoma

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CAT and CHMP

5.1.7. Nirogacestat (CAP MAA) - EMEA/H/C/006071, Orphan

Applicant: Springworks Therapeutics Ireland Limited

Scope (pre D-180 phase): Treatment of desmoid tumours

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.8. Pneumococcal polysaccharide conjugate vaccine (21-valent) (CAP MAA) - EMEA/H/C/006267

Scope (pre D-180 phase): For active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.9. Sargramostim (CAP MAA) - EMEA/H/C/006411

Scope (pre D-180 phase): Treatment for exposure to myelosuppressive doses of radiation

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.2. Medicines in the post-authorisation phase – PRAC-led procedures

5.2.1. Clopidogrel - GREPID (CAP) - EMEA/H/C/001059/II/0058

Applicant: Pharmathen S.A.

PRAC Rapporteur: Carla Torre

Scope: Submission of an RMP version 0.1 following procedure EMEA/H/C/001059/IB/0057/G

Action: For adoption of PRAC Assessment Report

5.2.2. Eculizumab - SOLIRIS (CAP) - EMEA/H/C/000791/WS2125/0133; Ravulizumab - ULTOMIRIS (CAP) - EMEA/H/C/004954/WS2125/0047

Applicant: Alexion Europe SAS

PRAC Rapporteur: Monica Martinez Redondo

Scope: Submission of an updated RMP version 21.0 for SOLIRIS and RMP version 9.0 for ULTOMIRIS in order to revise the controlled distribution additional risk minimisation measures and to add a new post-authorisation safety study (PASS) intended to evaluate the effectiveness of the revised additional risk minimisation measures for minimising the risk of meningococcal infections in the EU, following the PRAC outcome for PSUSA/00001198/202310 for SOLIRIS. The Annex II is updated accordingly. In addition, the MAH introduced minor updates to the SmPC to align the wording with the updated Annex II

Action: For adoption of PRAC Assessment Report

5.2.3. Obinutuzumab - GAZYVARO (CAP) - EMEA/H/C/002799/II/0059, Orphan

Applicant: Roche Registration GmbH

PRAC Rapporteur: Mari Thorn

Scope: Submission of an updated RMP version 10.0 in order to remove the guided questionnaires (GQ) for secondary malignancies, progressive multifocal leukoencephalopathy and hepatitis B reactivation as well as to update the ATC code and to introduce additional updates

Action: For adoption of PRAC Assessment Report

5.2.4. Panobinostat - FARYDAK (CAP) - EMEA/H/C/003725/II/0030, Orphan

Applicant: Pharmaand GmbH

PRAC Rapporteur: Sofia Trantza

Scope: Submission of an updated RMP version 7.0 in order to align the RMP with GVP V and GVP XVII. As a consequence, the MAH proposes to remove severe haemorrhage and severe infections (including sepsis/pneumonia/reactivation of hepatitis B infection) as important identified risks, and developmental toxicity, carcinogenicity/second primary malignancy (SPM), and medication error as important potential risks. In addition, the MAH proposes to revise the Annex II to reflect the removal of the Patient Card and educational programme as additional risk minimisation measures

Action: For adoption of PRAC Assessment Report

5.2.5. Tezepelumab - TEZSPIRE (CAP) - EMEA/H/C/005588/II/0013/G

Applicant: AstraZeneca AB

PRAC Rapporteur: Eva Jirsová

Scope: A grouped application consisting of:
Type II (C.I.11.b): Submission of an updated RMP version V 3, S 1 in order to remove the SUNRISE study (D5180C00024) from the RMP due to discontinuation of the study. This is a Phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre study to evaluate the efficacy and safety of tezepelumab 210 mg Q4W administered SC for 28 weeks using an accessorised pre-filled syringe, compared with placebo in reducing OCS use in OCS-dependent adult asthma participants. In addition, the MAH took the opportunity to implement updates to the Targeted Safety Questionnaires (TSQs) and to the Module SI of the RMP to bring it up to date.
Type IB (C.I.11.z): Submission of an updated RMP version V 3, S 1 in order to remove the DESTINATION study (D5180C00018) following procedure EMEA/H/C/005588/11/0004.
Type IB (C.I.11.z): Submission of an updated RMP version V 3, S 1 in order to propose changes to the study design and objectives for the Pregnancy PASS (D5180R00010), following procedure EMEA/H/C/005588/MEA/001.2.
Type IB (C.I.11.z): Submission of an updated RMP version V 3, S 1 in order to propose changes to the study design and objectives for the Cardiac PASS (D5180R00024), following procedure EMEA/H/C/005588/MEA/005

Action: For adoption of PRAC Assessment Report

5.3. Medicines in the post-authorisation phase – CHMP-led procedures

5.3.1. Acalabrutinib - CALQUENCE (CAP) - EMEA/H/C/005299/II/0025

Applicant: AstraZeneca AB

PRAC Rapporteur: Barbara Kovacic Bytyqi

Scope: Extension of indication to include CALQUENCE in combination with bendamustine and rituximab (BR) as treatment of adult patients with previously untreated Mantle Cell Lymphoma (MCL) based on interim results from study ACE-LY-308 (ECHO, D8220C00004); this is a Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma. As a consequence, sections 4.1, 4.2, 4.4, 4.8, and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 6, succession 1 of the RMP has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the SmPC. As part of the application the MAH is requesting a 1-year extension of the market protection

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.2. Acalabrutinib - CALQUENCE (CAP) - EMEA/H/C/005299/II/0026

Applicant: AstraZeneca AB

PRAC Rapporteur: Barbara Kovacic Bytyqi

Scope: Extension of indication to include CALQUENCE as monotherapy for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy based on final results from study ACE-LY-004 (D8225C00002); this is an open-label, phase 2 study of ACP-196 in subjects with Mantle Cell Lymphoma. As a consequence, sections 4.1 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 7 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial and formatting changes to the PI

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.3. Adagrasib - KRAZATI (CAP) - EMEA/H/C/006013/II/0010/G

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Kimmo Jaakkola

Scope: A grouped application consisting of:
C.I.4: Update of section 5.1 of the SmPC based on final results from study 849-012 (KRYSTAL-12) listed as a specific obligation in the Annex II. This is a Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation. The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted. In addition, the MAH took the opportunity to update Annex IIE of the PI.
C.I.4: Update of section 4.8 of the SmPC in order to update safety information based on an integrated analysis of data from interventional studies 849-012 (KRYSTAL-12), 849-007 (KRYSTAL-7) and 849-001 (KRYSTAL-1)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.4. Asciminib - SCEMBLIX (CAP) - EMEA/H/C/005605/II/0017, Orphan

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Eva Jirsová

Scope: Submission of a comprehensive final analysis of the data from study CABL001X2101, listed as a category 3 study in the RMP. This is a phase I, multicenter, open-label study of oral asciminib in patients with chronic myelogenous leukemia or Philadelphia Chromosome-positive acute lymphoblastic leukemia. The RMP version 2.0 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.5. Azacitidine - AZACITIDINE ACCORD (CAP) - EMEA/H/C/005147/X/0021

Applicant: Accord Healthcare S.L.U.

PRAC Rapporteur: Bianca Mulder

Scope: Extension application to introduce a new pharmaceutical form (film-coated tablet) associated with new strengths (200 and 300 mg) and new route of administration (oral use). The RMP (version 2.0) is updated in accordance

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.6. Blinatumomab - BLINCYTO (CAP) - EMEA/H/C/003731/II/0056, Orphan

Applicant: Amgen Europe B.V.

PRAC Rapporteur: Jana Lukacisinova

Scope: Extension of indication to include treatment as part of consolidation therapy for the treatment of patients with Philadelphia chromosome negative CD19 positive B-cell precursor ALL for BLINCYTO. The proposed indication is supported by efficacy data from Studies E1910, 20120215, and AALL1331, safety data for Studies E1910, 20120215, AALL1331, MT103-202, and MT103-203, and Pharmacokinetic data for Studies 20120215, AALL1331, MT103-202, MT103-203, and 20190360. As a consequence, sections 4.1, 4.2, 4.8, 5.1, and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 18.0 of the RMP has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.7. Bosutinib - BOSULIF (CAP) - EMEA/H/C/002373/X/0058/G

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Martin Huber

Scope: Extension application to introduce a new pharmaceutical form (hard capsules) associated with two new strengths (50 mg and 100 mg) grouped with an extension of indication (C.I.6.a) to include treatment of paediatric patients greater than or equal to 1 year of age with newly-diagnosed (ND) chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML) for BOSULIF, based on interim results from study ITCC-054/AAML1921 (BCHILD); this is a phase 1/2, multicenter, international, single-arm, open-label study of bosutinib in paediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ chronic myeloid leukemia. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated accordingly. Version 7.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the Product Information

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.8. Brentuximab vedotin - ADCETRIS (CAP) - EMEA/H/C/002455/II/0111, Orphan

Applicant: Takeda Pharma A/S

PRAC Rapporteur: Bianca Mulder

Scope: Extension of indication for ADCETRIS to include treatment for adult patients with previously untreated CD30+ Stage IIB with risk factors, Stage III or Stage IV HL in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD), based on final results from phase 3 study HD21 (NCT02661503). This study is titled Treatment Optimization Trial in the First-Line Treatment of Advanced-Stage Hodgkin Lymphoma; Comparison of 4-6 Cycles of Escalated BEACOPP With 4-6 Cycles of BrECADD. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 20.0 of the RMP has also been submitted.
In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet and to implement editorial changes to the SmPC

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.9. Cabotegravir - APRETUDE (CAP) - EMEA/H/C/005756/II/0004

Applicant: ViiV Healthcare B.V.

PRAC Rapporteur: Martin Huber

Scope: Update of sections 4.8, 5.1 and 5.2 of the SmPC to include data from clinical studies in HIV-1 uninfected adolescents (HPTN 083-01 and HPTN 084-01), updated data from the MOCHA study and updated PK data based on a population PK analysis of cabotegravir in adolescents in MOCHA, HPTN 083-01 and HPTN 084-01. In addition, the MAH took the opportunity to update section 4.2 of the SmPC to clarify the wording related to missed doses of oral PrEP and renal impairment, and to implement editorial changes in the SmPC. Furthermore, the MAH took the opportunity to align the PI with the latest QRD template version 10.4. The RMP version 1.1 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.10. Cabotegravir - VOCABRIA (CAP) - EMEA/H/C/004976/II/0022

Applicant: ViiV Healthcare B.V.

PRAC Rapporteur: Martin Huber

Scope: Extension of indication to include in combination with rilpivirine injection, the treatment of adolescents (at least 12 years of age and weighing at least 35 kg) for Vocabria, based on interim results from study 208580 (Phase I/II Study of the Safety, Acceptability, Tolerability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Injectable Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents). This is an ongoing Phase 1/Phase 2 multicenter, open-label, non-comparative study evaluating the safety, acceptability, tolerability, and PK of oral and LA

injectable CAB and LA injectable RPV in virologically suppressed HIV-infected adolescents 12 to <18 years of age and weighing at least 35 kg who are receiving stable cART consisting of 2 or more drugs from 2 or more classes of ARV drugs. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.1 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce editorial changes. Furthermore, the PI is brought in line with the latest QRD template version 10.4

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.11. Cabozantinib - CABOMETYX (CAP) - EMEA/H/C/004163/II/0040

Applicant: Ipsen Pharma

PRAC Rapporteur: Bianca Mulder

Scope: Extension of indication to include the treatment of adult patients with progressive extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumours after prior systemic therapy for CABOMETYX based on final results from study CABINET (A021602). This is a multicenter, two-arm, randomised, double-blind, placebo-controlled phase 3 study investigating cabozantinib versus placebo in patients with advanced Neuroendocrine Tumors (NET). As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.12. Chikungunya virus, strain delta5nsP3, live attenuated - IXCHIQ (CAP) - EMEA/H/C/005797/II/0001

Applicant: Valneva Austria GmbH

PRAC Rapporteur: Gabriele Maurer

Scope: Extension of indication to include active immunisation for the prevention of disease caused by chikungunya virus (CHIKV) in adolescents 12 years and older for IXCHIQ, based on interim 6 months results from study VLA1553-321; this is a randomized, double-blinded, multicentre study to evaluate the immunogenicity and safety of the adult dose of VLA1553 6 months following vaccination in adolescents from 12 years to less than 18 years of age after a single immunization. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.13. Covid-19 Vaccine (recombinant, adjuvanted) - BIMERVAX (CAP) - EMEA/H/C/006058/II/0017

Applicant: Hipra Human Health S.L.

PRAC Rapporteur: Zane Neikena

Scope: Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to update safety information and remove the warning for immunocompromised individuals, based on final

results from study HIPRA-HH-4 listed as a category 3 study in the RMP; this is a Phase IIb/III, open label, single arm, multi-centre trial to assess the immunogenicity and safety of an additional dose vaccination with a recombinant protein RBD fusion heterodimer candidate (PHH-1V) against SARS-CoV-2, in adults with pre-existing immunosuppressive conditions vaccinated against COVID-19. The Package Leaflet is updated accordingly. The RMP version 1.5 has also been submitted. In addition, the MAH took the opportunity to include information on excipient polysorbate 80, to introduce minor editorial changes to the PI and to bring the PI in line with QRD template version 10.4

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.14. Dalbavancin - XYDALBA (CAP) - EMEA/H/C/002840/II/0050

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Rugile Pilviniene

Scope: Extension of indication to include the treatment of acute bacterial skin and skin structure infections (ABSSSI) in paediatric patients from birth, including paediatric patients aged less than 3 months with suspected or confirmed sepsis associated with skin and subcutaneous tissue infections for Xydalba, based on final results from study DUR001-306, together with data from three Phase 1 PK studies (A8841004, DUR001-106, and DUR001-107 (DAL-PK-02); DUR001-306 was a Phase 3, multicenter, open-label, randomized, comparator controlled trial evaluating the safety and efficacy of a single dose of IV dalbavancin and a 2-dose regimen of once weekly IV dalbavancin (for a total of 14 days of coverage) for the treatment of ABSSSI known or suspected to be due to susceptible Gram-positive organisms in children. As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce minor editorial changes to the PI and to update the list of local representatives in the Package Leaflet in line with the latest QRD template version 10.4

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.15. Darvadstrocel - ALOFISEL (CAP) - EMEA/H/C/004258/II/0051/G, Orphan

Applicant: Takeda Pharma A/S, ATMP

PRAC Rapporteur: Gabriele Maurer

Scope: A grouped application comprised of 4 Type II Variations, as follows:
(C.I.4): Update of sections 4.8 and 5.1 of the SmPC in order to update the safety information, based on pooled safety data from the two phase 3 controlled studies (ADMIRE-CD & ADMIRE-CD II) and to update efficacy information based on final results from study ADMIRE-CD II, listed as an obligation in the Annex II. ADMIRE-CD II (Cx601-0303) is a Phase III randomised double blind, placebo controlled study to assess efficacy and safety of Cx601, adult allogeneic expanded adipose-derived stem cells (eASC) for the treatment of complex perianal fistula(s) in patients with Crohn's disease. The Annex II is updated accordingly. In addition, the MAH took the opportunity to introduce minor changes to the PI, including to section 4.2 of the SmPC and to the Package Leaflet.
3 x (C.I.13): Submission of interim results from studies Darvadstrocel-3003 and Alofisel-5003 (INSPIRE) and final results from study Darvadstrocel-3002 to support the benefit-risk

assessment of darvadstrocel based on all new available clinical data.
The RMP version 8.0 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CAT and CHMP

5.3.16. Dolutegravir - TIVICAY (CAP) - EMEA/H/C/002753/II/0093

Applicant: ViiV Healthcare B.V.

PRAC Rapporteur: Martin Huber

Scope: Submission of the final study report for Study ING112578 (IMPAACT P1093) (Category 3 PASS); an open-label, Phase 1/2 study designed to select a DTG dose for chronic dosing of infants, children, and adolescents based on PK, safety, and tolerability. As a consequence, a revised RMP version 20 has been provided and the MAH proposes to remove long-term safety data as an area of missing information

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.17. Dostarlimab - JEMPERLI (CAP) - EMEA/H/C/005204/II/0032

Applicant: GlaxoSmithKline (Ireland) Limited

PRAC Rapporteur: Carla Torre

Scope: Extension of indication for JEMPERLI to include, in combination with carboplatin and paclitaxel, the treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy based on Interim Analysis 1 and 2 from study RUBY Part 1 (213361). This is a phase 3, randomized, double-blind, controlled study evaluating the efficacy and safety of dostarlimab plus carboplatin and paclitaxel in primary advanced or recurrent EC versus placebo plus carboplatin and paclitaxel.
As a consequence, sections 4.1, 4.2, 4.4, 4.8, and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.0 of the RMP has also been submitted.
In addition, the Marketing authorisation holder (MAH) took the opportunity to implement editorial changes to the SmPC and to align the PI with the latest QRD template version 10.4

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.18. Elranatamab - ELREXFIO (CAP) - EMEA/H/C/005908/II/0005

Applicant: Pfizer Europe Ma EEIG

PRAC Rapporteur: Barbara Kovacic Bytyqi

Scope: Update of section 4.2 of the SmPC to add every four-week dosing schedule after at least 24 weeks of every two-week dosing and to update the recommendations for restarting therapy following dose delay, and update of sections 4.8, 5.1 and 5.2 of the SmPC with long-term efficacy, safety, and clinical pharmacology results (≥2 years of follow-up after the last participant initial dose), based on the final study report of Study C1071003; a Phase 2, open-label, multicentre, non-randomised study of elranatamab monotherapy in participants with MM who are refractory to at least one PI, one IMiD, and one anti-CD38 Ab. The Package Leaflet has been updated in accordance. In addition, the MAH took the opportunity to implement editorial changes in the SmPC and to update the list of local representatives in

the Package Leaflet. Further, the provision of the final study report addresses SOB 001, and Annex II has been updated accordingly. A revised RMP version 1.2 was provided as part of the application

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.19. Eltrombopag - REVOLADE (CAP) - EMEA/H/C/001110/II/0077

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Monica Martinez Redondo

Scope: Extension of indication to include second-line treatment of paediatric patients aged 2 years and above with acquired severe aplastic anaemia (SAA) for REVOLADE based on the ETB115E2201 (E2201) study primary analysis results; this is a paediatric phase II, open-label, uncontrolled, intra-patient dose escalation study to characterise the pharmacokinetics after oral administration of eltrombopag in paediatric patients with refractory, relapsed severe aplastic anaemia or recurrent aplastic anaemia. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 56.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.20. Etrasimod - VELSIPITY (CAP) - EMEA/H/C/006007/II/0002/G

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Karin Bolin

Scope: A grouped application comprised of two Type II variations, as follows:
C.I.4: Update of sections 4.2, 4.3 and 5.2 of the SmPC in order to amend recommendation regarding administration to patients with severe hepatic impairment and remove contraindication for severe hepatic impairment, based on in vitro studies to further characterise the drug-drug interaction (DDI) potential of metabolites M3 and M6. The Annex II and Package Leaflet are updated accordingly. The RMP version 1.2 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.
C.I.13: Submission of the final report from study 24GR036 (hERG Channel Automated Patch-Clamp Test); this is an assessment of the effects of PF-08034694, PF-08034742, PF-08039030, and PF-08039032 on the Kv11.1 (hERG) potassium current

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.21. Florbetaben (^{18}F) - NEURACEQ (CAP) - EMA/VR/0000227744

Applicant: Life Molecular Imaging GmbH

PRAC Rapporteur: Martin Huber

Scope: Extension of indication to include monitoring of the biological treatment response to pharmacological and non-pharmacological interventions for NEURACEQ, based on supporting literature. As a consequence, sections 4.1, 4.4 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 6.91 of the RMP has also been

submitted. In addition, the MAH took the opportunity to include the proposal to discontinue the inclusion of a paper copy of the SmPC with the product package

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.22. Guselkumab - TREMFYA (CAP) - EMEA/H/C/004271/II/0044

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Gabriele Maurer

Scope: Extension of indication for TREMFYA to include treatment of adult patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic treatment, based on results from GALAXI Phase 2/3 program and the GRAVITI Phase 3 study. GALAXI is a Phase 2/3, randomized, double-blind, placebo- and active-controlled, parallel-group, multicenter protocol to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active CD who have demonstrated an inadequate response or failure to tolerate previous conventional or biologic therapy. GRAVITI is a Phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of guselkumab SC induction therapy in participants with moderately to severely active CD.
As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1, 5.2, and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 10.1 of the RMP has also been submitted. As part of the application the MAH is requesting a 1-year extension of the market protection

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.23. Guselkumab - TREMFYA (CAP) - EMEA/H/C/004271/X/0043/G

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Gabriele Maurer

Scope: Extension application to:
- introduce a new pharmaceutical form (concentrate for solution for infusion), a new strength (200 mg) and a new route of administration (intravenous use);
- add a new strength of 200 mg for solution for injection (in pre-filled syringe / pre-filled pen) for subcutaneous use.
This application is grouped with a type II variation (C.I.6.a) to include the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor for Tremfya, based on results of a Phase 2b/3 clinical development programme (CNTO1959UCO3001) consisting of 3 separate studies, an Induction dose finding Study 1 Phase 2b, an Induction Study 2 Phase 3 and a Phase 3 Maintenance Study. These studies were randomized, double-blind, placebo-controlled, parallel-group, multicenter studies that evaluated the efficacy and safety of guselkumab in participants with moderately to severely active UC. As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC of the already approved form 100 mg solution for injection are updated. The Package Leaflet and Labelling are updated in accordance. Version 10.1 of the RMP has also been submitted. In addition, the MAH took

the opportunity to update the list of local representatives in the Package Leaflet and to introduce editorial changes to the PI

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.24. L-lysine hydrochloride, L-arginine hydrochloride - LYSAKARE (CAP) - EMEA/H/C/004541/II/0018

Applicant: Advanced Accelerator Applications

PRAC Rapporteur: Adam Przybylkowski

Scope: Update of sections 4.2, 4.3, 4.4, 4.8 and 5.1 of the SmPC in order to remove the contraindication and update the warning on 'Hyperkalaemia' as well as on 'Metabolic acidosis' and to update safety information based on final results from study CAAA001A12401 listed as a category 3 study in the RMP. This is a multicenter, open-label post authorization safety study to evaluate the effect of LysaKare infusion on serum potassium levels in GEP-NET patients eligible for Lutathera treatment. The RMP version 3.0 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.25. Mavacamten - CAMZYOS (CAP) - EMEA/H/C/005457/II/0011/G

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Kimmo Jaakkola

Scope: Grouped application comprised of 2 Type II Variations as follows:
C.I.4: Update of section 4.2 of the SmPC to change the echocardiography monitoring frequency once a patient is on a stable dose of mavacamten. The proposed update is supported by the clinical data from interim Clinical study report of MAVA-LTE (CV027-003) study: "A Long-term Safety Extension Study of Mavacamten in Adults with Hypertrophic Cardiomyopathy who have completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) trials", modelling & simulation results and safety data from post-approval safety database. The Package Leaflet is updated accordingly.
C.I.4: Update of section 4.2 of the SmPC to introduce the optional use of the Left ventricular outflow track (LVOT) gradient by post-exercise testing to guide dose titration for patient with specific characteristics. The proposed update is supported by the exposure-response modeling and simulation report with LVOT post-exercise gradient, based on the previously developed model with the data from the following studies: MYK-461-004 (PIONEER), MYK-461-005 (EXPLORER), MYK-461-007, MYK-461-008 (MAVA-LTE) and MYK-461-017 (VALOR).
The RMP version 4.0 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.26. Mirikizumab - OMVOH (CAP) - EMEA/H/C/005122/X/0006/G

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Sonja Hrabcik

Scope: Extension application to add a new strength of 200 mg grouped with an extension of

indication (C.I.6) to include treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment, for Omvoh, based mainly on final results from study I6T-MC-AMAM; this is a phase 3, multicenter, randomized, double-blind, placebo- and active-controlled, treat-through study to evaluate the efficacy and safety of mirikizumab in patients with moderately to severely active Crohn's disease. As a consequence, sections 1, 2, 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2, 5.3, 6.1, 6.5, 6.6 and 8 of the SmPC are updated. The Labelling and Package Leaflet are updated in accordance. Version 1.2 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes and to update the list of local representatives in the Package Leaflet. As part of the application, the MAH is requesting a 1-year extension of the market protection.
The following Quality variations are also included as part of this application:Type IA, A.5.b Type II, B.II.a.3.b.5 Type IB, B.II.b.4.a Type II, B.I.a.2.c Type IB, B.I.a.2.z

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.27. Naloxone - NYXOID (CAP) - EMEA/H/C/004325/II/0019

Applicant: Mundipharma Corporation (Ireland) Limited

PRAC Rapporteur: Liana Martirosyan

Scope: Submission of the interim report from the PAES MR903-9501 listed as an obligation in the Annex II, supported by Real World Evidence from literature and European Take-Home Naloxone programs (THN) demonstrating the effectiveness of Nyxoid in a real-world setting. Study MR903-9501 is a non-interventional multi-national, prospective, mixed methods study of the effectiveness of naloxone (including intranasal Nyxoid) administration by lay people in reversing opioid overdose. The Annex II and the RMP version 3.0 are updated accordingly. In addition, the MAH took the opportunity to introduce minor administrative changes to the Package Leaflet

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.28. Niraparib - ZEJULA (CAP) - EMEA/H/C/004249/II/0056, Orphan

Applicant: GlaxoSmithKline (Ireland) Limited

PRAC Rapporteur: Jan Neuhauser

Scope: Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from PRIMA study (PR-30-5017-C) listed as a PAES in the Annex II; this is a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy. The RMP version 9.0 has also been submitted. In addition, the MAH took the opportunity to update section D of Annex II, and to implement editorial changes to the PI

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.29. Nirmatrelvir, ritonavir - PAXLOVID (CAP) - EMEA/H/C/005973/II/0057/G

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Martin Huber

Scope: Grouped application consisting of:
C.I.4: Update of sections 4.2, 4.4, 4.8 and 5.2 of the SmPC in order to provide a new dosing recommendation in patients with severe renal impairment based on final results from study C4671028; this is a Phase 1, Open-Label, Non-Randomized Study to Investigate the Safety and PK Following Multiple Oral Doses of PF-07321332 (Nirmatrelvir)/Ritonavir in Adult Participants With COVID-19 and Severe Renal Impairment Either on Hemodialysis or Not on Hemodialysis. The Package Leaflet and Labelling are updated accordingly. The updated RMP version 3.1 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the SmPC.
B.II.e.5.a.2

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.30. Pemigatinib - PEMAZYRE (CAP) - EMEA/H/C/005266/II/0015, Orphan

Applicant: Incyte Biosciences Distribution B.V.

PRAC Rapporteur: Bianca Mulder

Scope: Extension of indication to include treatment of adults with myeloid/lymphoid neoplasms (MLNs) with Fibroblast Growth Factor Receptor1 (FGFR1) rearrangement for PEMAZYRE, based on final results from study INCB 54828-203 (FIGHT-203); this is a phase 2, open-label, monotherapy, multicenter study to evaluate the efficacy and safety of INCB054828 in subjects with myeloid/lymphoid neoplasms with FGFR1 rearrangement. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor changes to the PI. As part of the application, the MAH is requesting a 1-year extension of the market protection

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.31. Pregabalin - LYRICA (CAP) - EMEA/H/C/000546/X/0127

Applicant: Upjohn EESV

PRAC Rapporteur: Liana Martirosyan

Scope: Extension application to introduce a new pharmaceutical form (orodispersible tablet)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.32. Remdesivir - VEKLURY (CAP) - EMEA/H/C/005622/II/0053/G

Applicant: Gilead Sciences Ireland UC

PRAC Rapporteur: Eva Jirsová

Scope: Grouped application comprising two extensions of indication to include treatment of paediatric patients weighing at least 1.5 kg for VEKLURY, based on final results from study

GS-US-540-5823; this is a Phase 2/3 single-arm, open-label study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of remdesivir in participants from birth to < 18 years of age with COVID-19; as a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.1 of the RMP has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.33. Respiratory syncytial virus vaccine (bivalent, recombinant) - ABRYSVO (CAP) - EMEA/H/C/006027/II/0007

Applicant: Pfizer Europe Ma EEIG

PRAC Rapporteur: Liana Martirosyan

Scope: Extension of indication to include active immunization of individuals 18 through 59 years of age for ABRYSVO, based on final results from C3671023 Substudy A; this is a Phase 3 double-blinded, randomised, placebo-controlled study of safety, tolerability and immunogenicity of Abrysvo in participants ≥18 to <60 years of age at high risk of severe RSV disease due to certain chronic medical conditions. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the SmPC. Furthermore, as part of the application the MAH is requesting a 1-year extension of the market protection

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.34. Rilpivirine - REKAMBYS (CAP) - EMEA/H/C/005060/II/0022

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Liana Martirosyan

Scope: Extension of indication to include in combination with cabotegravir injection, the treatment of adolescents (at least 12 years of age and weighing at least 35 kg) for Rekambys, based on interim results from study 208580 (Phase I/II Study of the Safety, Acceptability, Tolerability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Injectable Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents). This is an ongoing Phase 1/Phase 2 multicenter, open-label, non-comparative study evaluating the safety, acceptability, tolerability, and PK of oral and LA injectable CAB and LA injectable RPV in virologically suppressed HIV-infected adolescents 12 to <18 years of age and weighing at least 35 kg who are receiving stable cART consisting of 2 or more drugs from 2 or more classes of ARV drugs. Consequently, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 5.1 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update a local representative in the Package Leaflet. Furthermore, the PI is brought in line with the latest QRD template version 10.4

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.35. Sacubitril, valsartan - ENTRESTO (CAP) - EMEA/H/C/004062/WS2738/0065; Sacubitril, valsartan - NEPARVIS (CAP) - EMEA/H/C/004343/WS2738/0062

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Karin Erneholm

Scope: Update of sections 4.8 and 5.3 of the SmPC in order to update information on long-term data in paediatric patients, based on final results from study CLCZ696B2319E1(PANAROMA-HF OLE) listed as a category 3 study in the RMP (MEA/009); this is a phase 3, multicenter, uncontrolled study to evaluate long-term safety and tolerability of open label sacubitril/valsartan in paediatric patients with heart failure due to systemic left ventricle systolic dysfunction who have completed study CLCZ696B2319 (PANORAMA-HF); the RMP version 8 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.36. Selpercatinib - RETSEVMO (CAP) - EMEA/H/C/005375/X/0031

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Bianca Mulder

Scope: Extension application to introduce a new pharmaceutical form (film-coated tablets) associated with new strengths (40 mg, 80 mg, 120 mg and 160 mg).
The RMP (version 7.1) is updated in accordance

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.37. Sugammadex - BRIDION (CAP) - EMEA/H/C/000885/II/0047

Applicant: Merck Sharp & Dohme B.V.

PRAC Rapporteur: Terhi Lehtinen

Scope: Extension of indication to include treatment of paediatric patients from birth to less than 2 years of age for Bridion based on final results from paediatric study PN169 (MK-8616-P169); this is a Phase 4 double-blinded, randomized, active comparator-controlled clinical trial to study the efficacy, safety, and pharmacokinetics of sugammadex (MK-8616) for reversal of neuromuscular blockade in pediatric participants aged birth to <2 years. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.1 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet, to implement minor editorial corrections and to update the information intended for healthcare professionals (HCPs) at the end of the Package Leaflet

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.38. Trientine - CUFENCE (CAP) - EMEA/H/C/004111/II/0020

Applicant: Univar Solutions BV

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Submission of the PK/PD sub-study report for study UNV-TR-004 (UNITED) listed as a PAES in the Annex II of the Product Information. This is an open label, prospective study to characterize the pharmacokinetics and pharmacodynamics of Cufence and to investigate the efficacy and safety in Wilson's disease. The Annex II and the RMP (version 5.0) are updated accordingly

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

6. Periodic safety update reports (PSURs)

6.1. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) only

6.1.1. Abaloparatide - ELADYNOS (CAP) - PSUSA/00011029/202404

Applicant: Theramex Ireland Limited

PRAC Rapporteur: Karin Erneholm

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.2. Andexanet alfa - ONDEXXYA (CAP) - PSUSA/00010764/202404

Applicant: AstraZeneca AB

PRAC Rapporteur: Bianca Mulder

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.3. Asciminib - SCEMBLIX (CAP) - PSUSA/00011008/202404

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Eva Jirsová

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.4. Capmatinib - TABRECTA (CAP) - PSUSA/00011022/202405

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Carla Torre

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.5. Cerliponase alfa - BRINEURA (CAP) - PSUSA/00010596/202404

Applicant: BioMarin International Limited

PRAC Rapporteur: Mari Thorn

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.6. Conestat alfa - RUCONEST (CAP) - PSUSA/00000873/202404

Applicant: Pharming Group N.V

PRAC Rapporteur: Jan Neuhauser

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.7. Delamanid - DELTYBA (CAP) - PSUSA/00010213/202404

Applicant: Otsuka Novel Products GmbH

PRAC Rapporteur: Jo Robays

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.8. Dostarlimab - JEMPERLI (CAP) - PSUSA/00010931/202404

Applicant: GlaxoSmithKline (Ireland) Limited

PRAC Rapporteur: Carla Torre

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.9. Durvalumab - IMFINZI (CAP) - PSUSA/00010723/202404

Applicant: AstraZeneca AB

PRAC Rapporteur: David Olsen

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.10. Efbemalenograstim alfa - RYZNEUTA (CAP) - PSUSA/00000286/202405

Applicant: Evive Biotechnology Ireland Limited

PRAC Rapporteur: Bianca Mulder

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.11. Empagliflozin- JARDIANCE (CAP); empagliflozin, metformin - SYNJARDY (CAP) - PSUSA/00010388/202404

Applicant: Boehringer Ingelheim International GmbH

PRAC Rapporteur: Maria del Pilar Rayon

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.12. Epoetin theta - BIOPOIN (CAP); EPORATIO (CAP) - PSUSA/00001240/202404

Applicant: TEVA GmbH (Biopoin), ratiopharm GmbH (Eporatio)

PRAC Rapporteur: Tiphaine Vaillant

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.13. Erenumab - AIMOVIG (CAP) - PSUSA/00010699/202405

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Terhi Lehtinen

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.14. Everolimus[4] - VOTUBIA (CAP) - PSUSA/00001343/202403

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.15. Exagamglogene autotemcel - CASGEVY (CAP) - PSUSA/00000244/202405

Applicant: Vertex Pharmaceuticals (Ireland) Limited, ATMP

PRAC Rapporteur: Bianca Mulder

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CAT and CHMP

[4] Indicated for astrocytoma (SEGA), renal angiomyolipoma, refractory seizures

6.1.16. Exenatide - BYDUREON (CAP); BYETTA (CAP) - PSUSA/00009147/202403

Applicant: AstraZeneca AB

PRAC Rapporteur: Mari Thorn

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.17. Febuxostat - ADENURIC (CAP) - PSUSA/00001353/202404

Applicant: Menarini International Operations Luxembourg S.A.

PRAC Rapporteur: Jan Neuhauser

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.18. Fezolinetant - VEOZA (CAP) - PSUSA/00000231/202405

Applicant: Astellas Pharma Europe B.V.

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.19. Ivacaftor, tezacaftor, elexacaftor - KAFTRIO (CAP) - PSUSA/00010868/202404

Applicant: Vertex Pharmaceuticals (Ireland) Limited

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.20. Ivosidenib - TIBSOVO (CAP) - PSUSA/00011048/202405

Applicant: Les Laboratoires Servier

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.21. Japanese encephalitis virus (inactivated) - IXIARO (CAP) - PSUSA/00001801/202403

Applicant: Valneva Austria GmbH

PRAC Rapporteur: Gabriele Maurer

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.22. Latanoprost (eye drop emulsions containing CKC) - CATIOLANZE (CAP) - PSUSA/00000202/202405

Applicant: Santen Oy

PRAC Rapporteur: Jean-Michel Dogné

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.23. Lebrikizumab - EBGLYSS (CAP) - PSUSA/00000175/202405

Applicant: Almirall, S.A.

PRAC Rapporteur: Liana Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.24. Linzagolix choline - YSELTY (CAP) - PSUSA/00010998/202405

Applicant: Theramex Ireland Limited

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.25. Loncastuximab tesirine - ZYNLONTA (CAP) - PSUSA/00011027/202404

Applicant: Swedish Orphan Biovitrum AB (publ)

PRAC Rapporteur: Eva Jirsová

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.26. Mavacamten - CAMZYOS (CAP) - PSUSA/00000074/202404

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Kimmo Jaakkola

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.27. Niraparib, abiraterone acetate - AKEEGA (CAP) - PSUSA/00011051/202404

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Jan Neuhauser

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.28. Nirsevimab - BEYFORTUS (CAP) - PSUSA/00011026/202404

Applicant: Sanofi Winthrop Industrie

PRAC Rapporteur: Kimmo Jaakkola

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.29. Palopegteriparatide - YORVIPATH (CAP) - PSUSA/00000173/202405

Applicant: Ascendis Pharma Bone Diseases A/S

PRAC Rapporteur: Lina Seibokiene

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.30. Parathyroid hormone - NATPAR (CAP) - PSUSA/00010591/202404

Applicant: Takeda Pharmaceuticals International AG Ireland Branch

PRAC Rapporteur: Rhea Fitzgerald

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.31. Pegunigalsidase alfa - ELFABRIO (CAP) - PSUSA/00011049/202405

Applicant: Chiesi Farmaceutici S.p.A.

PRAC Rapporteur: Liana Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.32. Potassium citrate, potassium hydrogen carbonate - SIBNAYAL (CAP) - PSUSA/00010932/202404

Applicant: Advicenne

PRAC Rapporteur: Adam Przybylkowski

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.33. Propranolol[5] - HEMANGIOL (CAP) - PSUSA/00010250/202404

Applicant: Pierre Fabre Medicament

PRAC Rapporteur: Monica Martinez Redondo

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.34. Recombinant vesicular stomatitis virus - Zaire ebolavirus vaccine (live) - ERVEBO (CAP) - PSUSA/00010834/202405

Applicant: Merck Sharp & Dohme B.V.

PRAC Rapporteur: Liana Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.35. Regadenoson - RAPISCAN (CAP) - PSUSA/00002616/202404

Applicant: GE Healthcare AS

PRAC Rapporteur: Maria del Pilar Rayon

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.36. Remdesivir - VEKLURY (CAP) - PSUSA/00010840/202405

Applicant: Gilead Sciences Ireland UC

PRAC Rapporteur: Eva Jirsová

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.37. Respiratory syncytial virus, glycoprotein f, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E - AREXVY (CAP) - PSUSA/00000031/202405

Applicant: GlaxoSmithkline Biologicals S.A.

PRAC Rapporteur: Maria del Pilar Rayon

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.38. Ripretinib - QINLOCK (CAP) - PSUSA/00010962/202405

Applicant: Deciphera Pharmaceuticals (Netherlands) B.V.

[5] Centrally authorised product(s) only

PRAC Rapporteur: Barbara Kovacic Bytyqi

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.39. Sacituzumab govitecan - TRODELVY (CAP) - PSUSA/00010959/202404

Applicant: Gilead Sciences Ireland UC

PRAC Rapporteur: Bianca Mulder

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.40. Selpercatinib - RETSEVMO (CAP) - PSUSA/00010917/202405

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Bianca Mulder

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.41. Sirolimus[6] - HYFTOR (CAP) - PSUSA/00000025/202405

Applicant: Plusultra pharma GmbH

PRAC Rapporteur: Mari Thorn

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.42. Tafamidis - VYNDAQEL (CAP) - PSUSA/00002842/202405

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Tiphaine Vaillant

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.43. Temoporfin - FOSCAN (CAP) - PSUSA/00002885/202404

Applicant: biolitec Pharma Ltd

PRAC Rapporteur: Bianca Mulder

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

[6] Indicated for treatment of angiofibroma associated with tuberous sclerosis complex only

6.1.44. Temsirolimus - TORISEL (CAP) - PSUSA/00002887/202403

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.45. Tirzepatide - MOUNJARO (CAP) - PSUSA/00011019/202405

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Bianca Mulder

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.46. Tremelimumab - IMJUDO (CAP) - PSUSA/00011038/202404

Applicant: AstraZeneca AB

PRAC Rapporteur: David Olsen

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.47. Vamorolone - AGAMREE (CAP) - PSUSA/00000223/202404

Applicant: Santhera Pharmaceuticals (Deutschland) GmbH

PRAC Rapporteur: Rhea Fitzgerald

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.48. Volanesorsen - WAYLIVRA (CAP) - PSUSA/00010762/202405

Applicant: Akcea Therapeutics Ireland Limited

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.49. Zanubrutinib - BRUKINSA (CAP) - PSUSA/00010960/202405

Applicant: BeiGene Ireland Ltd

PRAC Rapporteur: Bianca Mulder

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.2. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) and nationally authorised products (NAPs)

6.2.1. Enoxaparin sodium - INHIXA (CAP); NAP - PSUSA/00010833/202404

Applicants: Techdow Pharma Netherlands B.V. (Inhixa), various

PRAC Rapporteur: Bianca Mulder

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.2.2. Eslicarbazepine acetate - ZEBINIX (CAP); NAP - PSUSA/00001267/202404

Applicants: Bial - Portela & Cª, S.A. (Zebinix), various

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.2.3. Everolimus [7]- AFINITOR (CAP); NAP - PSUSA/00010268/202403

Applicants: Novartis Europharm Limited (Afinitor), various

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.2.4. Fluticasone furoate - AVAMYS (CAP); NAP - PSUSA/00009154/202404

Applicants: GlaxoSmithKline (Ireland) Limited (Avamys), various

PRAC Rapporteur: Adam Przybylkowski

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.2.5. Tacrolimus[8] - ADVAGRAF (CAP); ENVARSUS (CAP); MODIGRAF (CAP); NAP - PSUSA/00002839/202403

Applicants: Astellas Pharma Europe B.V. (Advagraf, Modigraf), Chiesi Farmaceutici S.p.A. (Envarsus), various

[7] Indicated for advanced renal cell carcinoma, advanced breast cancer, advanced neuroendocrine tumours (gastrointestinal, lung, pancreatic cancers) (NET)
[8] Systemic formulation(s) only

PRAC Rapporteur: Eamon O'Murchu

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.2.6. Thiotepa - TEPADINA (CAP), THIOTEPA RIEMSER (CAP); NAP - PSUSA/00002932/202403

Applicants: ADIENNE S.r.l. S.U. (Tepadina), ESTEVE Pharmaceuticals GmbH (Thiotepa Riemser), various

PRAC Rapporteur: Tiphaine Vaillant

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.3. PSUR single assessment (PSUSA) procedures including nationally authorised products (NAPs) only

6.3.1. Ambrosia artemisiifolia[9] [10] [11] [12] (NAP) - PSUSA/00010693/202404

Applicant(s): various

PRAC Lead: Gabriele Maurer

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.2. Amlodipine besilate, ramipril (NAP); amlodipine, hydrochlorothiazide, ramipril (NAP); hydrochlorothiazide, ramipril (NAP) - PSUSA/00010774/202403

Applicant(s): various

PRAC Lead: Jan Neuhauser

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.3. Argipressin (NAP) - PSUSA/00010749/202403

Applicant(s): various

PRAC Lead: Terhi Lehtinen

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

[9] Allergen for therapy
[10] (302)
[11] Sublingual use only
[12] Medicinal product(s) authorised via decentralised procedure

6.3.4. Bupivacaine (NAP); bupivacaine, epinephrine (NAP)- PSUSA/00010335/202404

Applicant(s): various

PRAC Lead: Zane Neikena

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.5. Carmustine[13] (NAP) - PSUSA/00010349/202404

Applicant(s): various

PRAC Lead: Tiphaine Vaillant

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.6. Carteolol (NAP) - PSUSA/00000574/202403

Applicant(s): various

PRAC Lead: Anna Mareková

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.7. Chlorprothixene (NAP) - PSUSA/00000717/202403

Applicant(s): various

PRAC Lead: Zane Neikena

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.8. Ciprofloxacin, fluocinolone acetonide (NAP) - PSUSA/00000772/202404

Applicant(s): various

PRAC Lead: Maria del Pilar Rayon

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.9. Dihydroergotamine (NAP) - PSUSA/00001075/202404

Applicant(s): various

PRAC Lead: Adam Przybylkowski

[13] Powder and solvent for solution for infusion only

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.10. Fentanyl[14] (NAP) - PSUSA/00001370/202404

Applicant(s): various

PRAC Lead: Liana Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.11. Isotretinoin[15] (NAP) - PSUSA/00010488/202405

Applicant(s): various

PRAC Lead: Maia Uusküla

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.12. Ivermectin[16] (NAP) - PSUSA/00010376/202404

Applicant(s): various

PRAC Lead: Tiphaine Vaillant

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.13. Metformin (NAP) - PSUSA/00002001/202404

Applicant(s): various

PRAC Lead: Amimour Zoubida

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.14. Nebivolol (NAP) - PSUSA/00002129/202403

Applicant(s): various

PRAC Lead: Bianca Mulder

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

[14] Transdermal patches, solution for injection
[15] Oral formulations only
[16] Topical use only

6.3.15. Nitrendipine (NAP) - PSUSA/00002171/202403

Applicant(s): various

PRAC Lead: Jan Neuhauser

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.16. Ofloxacin[17] (NAP) - PSUSA/00002204/202404

Applicant(s): various

PRAC Lead: Petar Mas

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.17. Oxaliplatin (NAP) - PSUSA/00002229/202404

Applicant(s): various

PRAC Lead: Tiphaine Vaillant

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.18. Promestriene[18] (NAP) - PSUSA/00009271/202403

Applicant(s): various

PRAC Lead: Irina Sandu

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.19. Promethazine (NAP) - PSUSA/00002545/202404

Applicant(s): various

PRAC Lead: Eva Jirsová

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

[17] Topical use only
[18] Cream and vaginal capsule(s) only

6.4. Follow-up to PSUR/PSUSA procedures

6.4.1. Dolutegravir - TIVICAY (CAP) - EMEA/H/C/002753/LEG 015.6

Applicant: ViiV Healthcare B.V.

PRAC Rapporteur: Martin Huber

Scope: MAH's response to LEG 015.4 [2nd Annual Report, RESPOND study] RSI as adopted in April 2024. In relation to the 2nd annual report for the RESPOND study and in view of the new data regarding diabetes mellitus and the use of INSTIs, the MAH should discuss this issue in detail as soon as corresponding publications are available. This should be provided no later than 30 days after the receipt of these data

Action: For adoption of advice to CHMP

6.4.2. Dolutegravir, abacavir, lamivudine - TRIUMEQ (CAP) - EMEA/H/C/002754/LEG 010.6

Applicant: ViiV Healthcare B.V.

PRAC Rapporteur: Martin Huber

Scope: MAH's response to LEG 010.4 [2nd Annual Report, RESPOND study] RSI as adopted in April 2024. In relation to the 2nd annual report for the RESPOND study and in view of the new data regarding diabetes mellitus and the use of INSTIs, the MAH should discuss this issue in detail as soon as corresponding publications are available. This should be provided no later than 30 days after the receipt of these data

Action: For adoption of advice to CHMP

6.4.3. Dolutegravir, lamivudine - DOVATO (CAP) - EMEA/H/C/004909/LEG 005.6

Applicant: ViiV Healthcare B.V.

PRAC Rapporteur: David Olsen

Scope: MAH's response to LEG 005.4 [2nd Annual Report, RESPOND study] RSI as adopted in April 2024. In relation to the 2nd annual report for the RESPOND study and in view of the new data regarding diabetes mellitus and the use of INSTIs, the MAH should discuss this issue in detail as soon as corresponding publications are available. This should be provided no later than 30 days after the receipt of these data

Action: For adoption of advice to CHMP

6.5. Variation procedure(s) resulting from PSUSA evaluation

6.5.1. Blinatumomab - BLINCYTO (CAP) - EMEA/H/C/003731/II/0054, Orphan

Applicant: Amgen Europe B.V.

PRAC Rapporteur: Jana Lukacisinova

Scope: To update sections 4.2, 4.4, 4.8 of the SmPC to include Immune Effector Cell-

Associated Neurotoxicity Syndrome (ICANS); and to update section D of Annex II to remove educational materials for physicians, pharmacists and nurses and to include ICANS within neurologic events in educational material for patient/caregivers and patient alert card following the outcome of PSUR procedure EMEA/H/C/PSUSA/00010460/202212. The Package Leaflet is updated accordingly. The RMP version 17.0 has also been submitted

Action: For adoption of PRAC Assessment Report

6.5.2. Human thrombin, human fibrinogen - TACHOSIL (CAP) - EMEA/H/C/000505/II/0131

Applicant: Corza Medical GmbH

PRAC Rapporteur: Gabriele Maurer

Scope: Update of section 4.2 of the SmPC to emphasise correct product handling and section 4.8 of the SmPC to reflect the fact that cases of product non-adhesion issues have been reported, upon request by PRAC following the outcome of the PSUR procedure EMEA/H/C/PSUSA/00010297/202306. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC

Action: For adoption of PRAC Assessment Report

6.6. Expedited summary safety reviews[19]

None

7. Post-authorisation safety studies (PASS)

7.1. Protocols of PASS imposed in the marketing authorisation(s)[20]

7.1.1. Alemtuzumab - LEMTRADA (CAP) - EMEA/H/C/PSA/S/0107.2

Applicant: Sanofi Belgium

PRAC Rapporteur: Karin Erneholm

Scope: Substantial amendment to a non-interventional post-authorisation safety study to investigate drug utilisation and safety monitoring patterns for Lemtrada (alemtuzumab) [MAH's response to PSA/S/0107.1]

Action: For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.2. Tabelecleucel – EBVALLO (CAP) - EMEA/H/C/PSA/S/0115.1

Applicant: Pierre Fabre Medicament

PRAC Rapporteur: Amelia Cupelli

[19] Submission of expedited summary safety reports for review in addition to the requirements for submission of PSUR(s) falling within the pandemic period and requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC

[20] In accordance with Article 107n of Directive 2001/83/EC

Scope: Substantial amendment to an observational, Post-Authorisation Safety Study (PASS) to describe the safety and effectiveness of tabelecleucel in patients with Epstein-Barr Virus positive (EBV+) Post-Transplant Lymphoproliferative Disease (PTLD) in a real-world setting in Europe [MAH's response to PSA/S/0115]

Action: For adoption of PRAC Assessment Report, PRAC outcome letter

7.2. Protocols of PASS non-imposed in the marketing authorisation(s)[21]

7.2.1. Dexmedetomidine - DEXDOR (CAP) - EMEA/H/C/002268/LEG 016.7

Applicant: Orion Corporation

PRAC Rapporteur: Karin Bolin

Scope: ***REVISED PROTOCOL***
Draft Study Title: Post-hoc analysis of the SPICE III (academic) trial dataset to address the risk of increased mortality among patients ≤65y sedated with dexmedetomidine. (category 3 study)

Action: For adoption of advice to CHMP

7.2.2. Nivolumab - OPDIVO (CAP) - EMEA/H/C/003985/MEA 057.2

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Martin Huber

Scope: MAH Response to MEA 057.1 [***Protocol PASS Study no.: CA184557***] RSI as adopted in June 2024.
Title: Long-term Follow-up of Nivolumab and Ipilimumab (as Monotherapy and as Combination Therapy)-treated Pediatric Patients Enrolled in the Dutch Melanoma Treatment Registry (DMTR).
Further clarification is needed whether the legal requirements are met to include paediatric patients < 12 years of age as a separate off label use cohort, as well as the support from PDCO

Action: For adoption of advice to CHMP

7.2.3. Risankizumab - SKYRIZI (CAP) - EMEA/H/C/004759/MEA 002.6

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Liana Martirosyan

Scope: From Initial MAA:
Progress Report /PASS Study P16-751:
Pregnancy Exposures and Outcomes in Psoriasis Patients Treated with Risankizumab: A Cohort Study Utilising Large Healthcare Databases with Mother-Baby Linkage in the United

[21] In accordance with Article 107m of Directive 2001/83/EC, supervised by PRAC in accordance with Article 61a (6) of Regulation (EC) No 726/2004

States.

Action: For adoption of advice to CHMP

7.2.4. Single-stranded 5' capped mRNA encoding the Respiratory syncytial virus glycoprotein F stabilized in the prefusion conformation - MRESVIA (CAP) - EMEA/H/C/006278/MEA 003

Applicant: Moderna Biotech Spain S.L.

PRAC Rapporteur: Jean-Michel Dogné

Scope: ***PASS Draft Study Protocol / mRNA-1345-P902 and mRNA-1345-P903***(RMP (v. 0.4))
mRNA-1345-P902: Post-Authorization Active Surveillance Safety Study Using Secondary Data to Monitor Real-World Safety of the mRNA-1345 Vaccine for respiratory syncytial virus (RSV) in the United States.

mRNA-1345-P903: Post-Authorization Active Surveillance Safety Study Using Secondary Data to Monitor Real-World Safety of the mRNA-1345 Vaccine for respiratory syncytial virus (RSV) in Europe

Action: For adoption of advice to CHMP

7.2.5. Tozinameran - COMIRNATY (CAP) - EMEA/H/C/005735/MEA 041.7

Applicant: BioNTech Manufacturing GmbH

PRAC Rapporteur: Liana Martirosyan

Scope: ***Fourth Protocol Amendment*** / Study C4591036
category 3 study as per RMP based on the Data and Safety Monitoring Board Report (DSMB).
Clinical study to characterize the clinical course, risk factors, long-term sequelae, and quality of life in children and young adults <21 years with acute post-vaccine myocarditis. (StudyC4591036).
Also includes DSMB review to the 4th Protocol Amendment for study C4591036

Action: For adoption of advice to CHMP

7.2.6. Tozinameran - COMIRNATY (CAP) - EMEA/H/C/005735/MEA 047.5

Applicant: BioNTech Manufacturing GmbH

PRAC Rapporteur: Liana Martirosyan

Scope: ***Protocol amendment / Justification for extension of a milestone for study C4591038***
Change request of due date of Final study report from September 2024 to 30 June 2025.
Study C4591038, a category 3 study in the RMP:
Non-interventional study C4591038 - Post Conditional approval active surveillance study among individuals in Europe receiving the Pfizer BioNTech Coronavirus Disease 2019 (COVID-19) vaccine. Sub-study to investigate natural history of postvaccination myocarditis and pericarditis

Action: For adoption of advice to CHMP

7.2.7. Ublituximab - BRIUMVI (CAP) - EMEA/H/C/005914/MEA 001.3

Applicant: Neuraxpharm Pharmaceuticals S.L.

PRAC Rapporteur: Liana Martirosyan

Scope: MAH's responses to MEA 001.2 [***Revised Protocol***/ Study A Long-Term Observational Study of the Safety of Ublituximab Patients with Relapsing Multiple Sclerosis in a Real-World Setting (ENLIGHTEN)] as adopted in June 2024

Action: For adoption of advice to CHMP

7.2.8. Ublituximab - BRIUMVI (CAP) - EMEA/H/C/005914/MEA 002.2

Applicant: Neuraxpharm Pharmaceuticals S.L.

PRAC Rapporteur: Liana Martirosyan

Scope: MAH's responses to MEA 002.1 [***Revised Protocol / Study No TG1101-RMS403***] as adopted in June 2024.
Pregnancy Registry: A Prospective Registry Study of Pregnancy and Infant Outcomes in Patients Treated with BRIUMVI

Action: For adoption of advice to CHMP

7.2.9. Ublituximab - BRIUMVI (CAP) - EMEA/H/C/005914/MEA 003.2

Applicant: Neuraxpharm Pharmaceuticals S.L.

PRAC Rapporteur: Liana Martirosyan

Scope: MAH's responses to MEA 003.1 [***Revised Protocol*** / Study No TG1101-RMS404] as adopted in June 2024.
To Characterize the Safety of Briumvi Use in Pregnant Patients with Multiple Sclerosis Using Data from a US Administrative Healthcare Claims Database

Action: For adoption of advice to CHMP

7.3. Results of PASS imposed in the marketing authorisation(s)[22]

7.3.1. Aclidinium – BRETARIS GENUAIR (CAP), EKLIRA GENUAIR (CAP); aclidinium, formoterol fumarate dihydrate – BRIMICA GENUAIR (CAP), DUAKLIR GENUAIR - (CAP) - EMEA/H/C/PSR/S/0047

Applicant: Covis Pharma Europe B.V.

PRAC Rapporteur: Adam Przybylkowski

Scope: Final study report for a post-authorisation safety study to evaluate the potential cardiovascular safety concerns and all-cause mortality described in the risk management plan for aclidinium bromide as monotherapy and fixed-dose combination of

[22] In accordance with Article 107p-q of Directive 2001/83/EC

aclidinium/formoterol

Action: For adoption of recommendation to CHMP

7.3.2. Alemtuzumab - LEMTRADA (CAP) - EMEA/H/C/PSR/S/0050

Applicant: Sanofi Belgium

PRAC Rapporteur: Karin Erneholm

Scope: Final study report for a non-interventional post-authorisation safety study to investigate drug utilisation and safety monitoring patterns for Lemtrada (alemtuzumab)

Action: Request for supplementary information (RSI)

7.4. Results of PASS non-imposed in the marketing authorisation(s)[23]

7.4.1. Brexucabtagene autoleucel - TECARTUS (CAP) - EMEA/H/C/005102/II/0051, Orphan

Applicant: Kite Pharma EU B.V., ATMP

PRAC Rapporteur: Bianca Mulder

Scope: Submission of the final study report for the non-interventional study KT-EU-472-5966 titled "Quantitative Testing of Health Care Professional Knowledge About Tecartus Risk Minimisation Measures'' listed as a category 3 study in the RMP

Action: For adoption of PRAC Assessment Report

7.4.2. COVID-19 mRNA vaccine - SPIKEVAX (CAP) - EMEA/H/C/005791/II/0131

Applicant: Moderna Biotech Spain S.L.

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Submission of the final report from study mRNA-1273-919 - An Observational Study to Assess Maternal and Infant Outcomes Following Exposure to Spikevax During Pregnancy, listed as a category 3 study in the RMP

Action: For adoption of PRAC Assessment Report

7.4.3. COVID-19 mRNA vaccine - SPIKEVAX (CAP) - EMEA/H/C/005791/II/0142

Applicant: Moderna Biotech Spain S.L.

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Submission of the final report from study mRNA-1273-P920 – US PASS (Post Authorization Safety Study in the US) listed as a category 3 study in the RMP; this is a post-marketing safety of elasomeran/davesomeran and andusomeran vaccines in the United States

[23] In accordance with Article 61a (6) of Regulation (EC) No 726/2004, in line with the revised variations regulation for any submission as of 4 August 2013

Action: For adoption of PRAC Assessment Report

7.4.4. Deferasirox - EXJADE (CAP) - EMEA/H/C/000670/II/0090

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Tiphaine Vaillant

Scope: Update of section 4.2 of the SmPC in order to update information on posology based on the non-interventional study CICL670A2429 listed as a category 3 study in the RMP. This is a survey to assess physicians' knowledge of Exjade posology and biological monitoring recommendations as described in the Educational Materials (EMs)

Action: For adoption of PRAC Assessment Report

7.4.5. Dengue tetravalent vaccine (live, attenuated) - DENGVAXIA (CAP) - EMEA/H/C/004171/II/0032

Applicant: Sanofi Pasteur

PRAC Rapporteur: Sonja Hrabcik

Scope: Submission of the final study report for DNG16 (category 3 PASS); a non-interventional Pregnancy Registry for DENGVAXIA, CYD-TDV Dengue Vaccine used to evaluate the safety of CYD-TDV in pregnant women and their offsprings inadvertently exposed during pregnancy or up to 30 days preceding their last menstrual period with regards to maternal, pregnancy, birth, neonatal, and infant outcomes. This submission fulfills MEA/FSR 002

Action: For adoption of PRAC Assessment Report

7.4.6. Empagliflozin - JARDIANCE (CAP) - EMEA/H/C/002677/WS2713/0089; Empagliflozin, linagliptin - GLYXAMBI (CAP) - EMEA/H/C/003833/WS2713/0062; Empagliflozin, metformin - SYNJARDY (CAP) - EMEA/H/C/003770/WS2713/0080

Applicant: Boehringer Ingelheim International GmbH

PRAC Rapporteur: Maria del Pilar Rayon

Scope: Submission of the final report from study 1245-0097. This is a post-authorisation safety study (PASS) to assess the risk of urinary tract malignancies in relation to empagliflozin exposure in patients with type 2 diabetes: a multi-database European study. The RMP versions 23.0, 17.0 and 11.0 are also submitted for Jardiance, Synjardy and Glyxambi, respectively

Action: For adoption of PRAC Assessment Report

7.4.7. Mepolizumab - NUCALA (CAP) - EMEA/H/C/003860/II/0071

Applicant: GlaxoSmithKline Trading Services Limited

PRAC Rapporteur: Gabriele Maurer

Scope: Submission of the final report from the Mepolizumab (Nucala) Pregnancy Exposure Study 200870: a VAMPSS post marketing surveillance study of Mepolizumab safety in

pregnancy, listed as a category 3 study in the RMP. This is a non-interventional study to monitor planned and unplanned pregnancies exposed to mepolizumab and to evaluate the possible teratogenic effect of this medication relative to the pregnancy outcomes of major birth defects, preterm delivery, small for gestational age infants and spontaneous abortion or stillbirth. The RMP version 13.0 has also been submitted

Action: For adoption of PRAC Assessment Report

7.4.8. Naloxegol - MOVENTIG (CAP) - EMEA/H/C/002810/II/0043

Applicant: Gruenenthal GmbH

PRAC Rapporteur: Eamon O'Murchu

Scope: Submission of the final report from the PASS study D3820R0008 listed as a category 3 study in the RMP. This is a US post-marketing, comparative, observational study to evaluate the cardiovascular safety of Naloxegol in patients with non-cancer pain in comparison to other treatments for opioid induced constipation. The RMP version 9.0 has also been submitted

Action: For adoption of PRAC Assessment Report

7.4.9. Naltrexone hydrochloride, bupropion hydrochloride - MYSIMBA (CAP) - EMEA/H/C/003687/II/0066

Applicant: Orexigen Therapeutics Ireland Limited

PRAC Rapporteur: Martin Huber

Scope: Submission of final report from study NB-453 study, listed as a category 3 study in the RMP. This is a non-interventional qualitative research using online focus groups to assess understanding, attitude and behaviour for usage of the Mysimba Physician Prescribing Checklist (PPC) among physicians in the European Union (EU), following a previous cross-sectional survey that aimed at evaluating the effectiveness of the same PPC (Study NB-452). The RMP version 12.10 has also been submitted

Action: For adoption of PRAC Assessment Report

7.4.10. Piperaquine tetraphosphate, artenimol - EURARTESIM (CAP) - EMEA/H/C/001199/II/0040/G

Applicant: Alfasigma S.p.A.

PRAC Rapporteur: Martin Huber

Scope: C.I.13: Submission of the final report from the effectiveness evaluation survey for Eurartesim (protocol no. 3366) listed as a category 3 study in the RMP. This is a European multi-centre online survey to assess physician understanding of the revised edition of the educational material. Consequential changes to RMP version 16.1 have been implemented. C.I.11.b: Submission of an updated RMP version 16.1 in order to delete "Severe Malaria" from the Missing Information

Action: For adoption of PRAC Assessment Report

7.4.11. Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted) - MOSQUIRIX (Art 58[24]) - EMEA/H/W/002300/II/0085/G

Applicant: GlaxoSmithkline Biologicals SA

PRAC Rapporteur: Jean-Michel Dogné

Scope: A grouped application comprised of two type II variations, as follows:

C.I.4: Update of sections 4.4 and 5.1 of the SmPC in order to remove meningitis from the list of important potential risks and add effectiveness data based on EPI-MAL-003 study listed as a category 3 study in the RMP. This is a prospective study to evaluate the safety, effectiveness and impact of the RTS,S/AS01E vaccine in young children in sub-Saharan Africa countries. The Package Leaflet is updated accordingly.
The RMP version 6.0 has also been submitted.
C.I.13: Submission of the final report from study MVPE (Malaria Vaccine Pilot Evaluation) listed as a category 3 study in the RMP. This is a observational study in the context of a cluster-randomized pilot implementation in order to assess the feasibility of delivery, safety, and impact on mortality of the RTS,S/AS01E malaria vaccine delivered through the routine immunization services in Kenya, Malawi, and Ghana over 4 years

Action: For adoption of PRAC Assessment Report

7.4.12. Vedolizumab - ENTYVIO (CAP) - EMEA/H/C/002782/II/0086

Applicant: Takeda Pharma A/S

PRAC Rapporteur: Adam Przybylkowski

Scope: Submission of amendment 2 (version 3) to the final clinical study report (CSR) for the post authorisation safety study MLN0002-401, listed as a category 3 study in the RMP. This was a prospective, observational, international, multicenter, cohort study comparing vedolizumab with other biologic agents in patients with UC or CD. The final CSR (versions 1 and 2) was submitted and assessed in procedure EMEA/H/C/002782/II/0073. Further review and additional inconsistencies were identified in the analyses and reporting of safety, which are addressed in CSR amendment 2 (version 3)

Action: For adoption of PRAC Assessment Report

7.4.13. Zanamivir - DECTOVA (CAP) - EMEA/H/C/004102/II/0020

Applicant: GlaxoSmithKline Trading Services Limited

PRAC Rapporteur: Mari Thorn

Scope: Submission of the final report from study 208140 listed as a category 3 PASS in the RMP. This is an observational study of the safety of zanamivir 10 mg/ml solution for infusion exposure in pregnant women with complicated influenza and their offspring. The RMP version 8.0 has also been submitted

Action: For adoption of PRAC Assessment Report

[24] Article 58 of Regulation (EC) No 726/2004 allows the Committee for Medicinal Products for Human Use (CHMP) to give opinions, in co-operation with the World Health Organisation (WHO) on medicinal products for human use that are intended exclusively for markets outside of the European Union (EU)

7.5. Interim results of imposed and non-imposed PASS submitted before the entry into force of the revised variation regulation

7.5.1. Burosumab - CRYSVITA (CAP) - EMEA/H/C/004275/MEA 004.5

Applicant: Kyowa Kirin Holdings B.V.

PRAC Rapporteur: Gabriele Maurer

Scope: MAH's response to MEA 004.4 [***Second interim study report*** [Study No EUPAS32190]] RSI as adopted in July 2024.
Non-interventional Post-Authorisation Safety Study of Burosumab in the Treatment of Children >1 year of age, Adolescents and Adults with X-linked Hypophosphataemia (protocol number 2019-36-EU-CRY)

Action: For adoption of advice to CHMP

7.5.2. Ciltacabtagene autoleucel - CARVYKTI (CAP) - EMEA/H/C/005095/ANX 003.3

Applicant: Janssen-Cilag International NV, ATMP

PRAC Rapporteur: Jo Robays

Scope: From initial MAA
PASS Study 68284528MMY4004
Title: An Observational Post-authorization Safety Study to Evaluate the Safety of Multiple Myeloma Patients Treated with Ciltacabtagene Autoleucel.
Second Interim Report / Study 68284528MMY4004

Action: For adoption of advice to CHMP

7.5.3. Hydroxycarbamide - SIKLOS (CAP) - EMEA/H/C/000689/MEA 035.2

Applicant: Theravia

PRAC Rapporteur: Jo Robays

Scope: ESCORT-HU Extension:
European Sickle Cell Disease Cohort – Hydroxyurea (#2_V1.0)
Fourth Interim Report

Action: For adoption of advice to CHMP

7.5.4. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 001.10

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Tiphaine Vaillant

Scope: From Initial MAA: PASS Study No. OP0005: European non-interventional post-authorisation safety study (PASS) related to the adherence to the cardiovascular risk minimization measures for romosozumab, by the EU-ADR Alliance.
Six Interim Report / PASS Study No. OP0005

Action: For adoption of advice to CHMP

7.5.5. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 002.11

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Tiphaine Vaillant

Scope: From Initial MAA: PASS Study No. OP0004: European non-interventional post-authorisation safety study (PASS) related to serious cardiovascular adverse events of myocardial infarction and stroke for romosozumab by the EU-ADR Alliance to evaluate potential differences in terms of serious cardiovascular adverse events between romosozumab and currently available therapies used in comparable patients in real-world conditions.
SIXTH INTERIM REPORT / PASS Study No. OP0004

Action: For adoption of advice to CHMP

7.5.6. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 003.10

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Tiphaine Vaillant

Scope: From Initial MAA: PASS Study No. OP0006 European non-interventional post-authorisation safety study (PASS) related to serious infections risk for romosozumab by the EU-ADR Alliance to evaluate potential differences in terms of serious infection between romosozumab and currently available therapies used in comparable patients in real-world conditions.
FOURTH INTERIM REPORT (comparative) /PASS Study No. OP0006

Action: For adoption of advice to CHMP

7.5.7. Selumetinib - KOSELUGO (CAP) - EMEA/H/C/005244/SOB 004.1

Applicant: AstraZeneca AB

PRAC Rapporteur: Mari Thorn

Scope: Post-Authorisation Safety Study of Paediatric Patients Initiating Selumetinib: A Multiple-Country Prospective Cohort Study (Report 2)(Version number 1.0)
Second PASS Annual Progress / D1346R00004

The primary objective of this study is:
• To characterise the safety of selumetinib, including up to 6 years of long-term safety, in paediatric patients with NF1-related symptomatic, inoperable PN, 8 to < 18 years old who have not reached Tanner Stage V at the start of selumetinib treatment (Nested Prospective Cohort).
The secondary objective of this study is:
• To describe the paediatric population 3 to < 18 years old with NF1-related symptomatic inoperable PN who start selumetinib in routine clinical practice (Base Cohort)

Action: For adoption of advice to CHMP

7.5.8. Tofacitinib - XELJANZ (CAP) - EMEA/H/C/004214/MEA 013.6

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Liana Martirosyan

Scope: Interim study A3921344:
An Active Surveillance, Post-Authorization Study to Characterize the Safety of Tofacitinib in Patients with Moderately to Severely Active Ulcerative Colitis in the Real-World Setting Using Data from the Swedish Quality Register for Inflammatory Bowel Disease. (SWIBREG). (RMP category 3 study)
Second Interim Report

Action: For adoption of advice to CHMP

7.5.9. Tofacitinib - XELJANZ (CAP) - EMEA/H/C/004214/MEA 017.4

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Liana Martirosyan

Scope: ***Interim Report***/ Study A3921352
Study A3921352 is an active surveillance, post-authorization study to characterize the safety of tofacitinib in patients with moderately to severely active ulcerative colitis in the real-world setting using data from the United Registries for Clinical Assessment and Research (UR-CARE) in the European Union (EU)

Action: For adoption of advice to CHMP

7.5.10. Upadacitinib - RINVOQ (CAP) - EMEA/H/C/004760/MEA 013.5

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Petar Mas

Scope: ***Second Annual Progress Report*** and MAH's responses to MEA 013.4 [Protocol P20-390] RSI as adopted in December 2023. Cohort Study of Long-term Safety of Upadacitinib in the Treatment of Atopic Dermatitis in Denmark and Sweden (PASS Protocol P20-390)

Action: For adoption of advice to CHMP

7.6. Others

None

7.7. New Scientific Advice

7.8. Ongoing Scientific Advice

7.9. Final Scientific Advice (Reports and Scientific Advice letters)

8. Renewals of the marketing authorisation, conditional renewal and annual reassessments

8.1. Annual reassessments of the marketing authorisation

8.1.1. Asfotase alfa - STRENSIQ (CAP) - EMEA/H/C/003794/S/0069 (without RMP)

Applicant: Alexion Europe SAS

PRAC Rapporteur: Eamon O'Murchu

Scope: Annual reassessment of the marketing authorisation

Action: For adoption of advice to CHMP

8.1.2. Cerliponase alfa - BRINEURA (CAP) - EMEA/H/C/004065/S/0047 (without RMP)

Applicant: BioMarin International Limited

PRAC Rapporteur: Mari Thorn

Scope: Annual reassessment of the marketing authorisation

Action: For adoption of advice to CHMP

8.1.3. Eladocagene exuparvovec - UPSTAZA (CAP) - EMEA/H/C/005352/S/0025 (without RMP)

Applicant: PTC Therapeutics International Limited, ATMP

PRAC Rapporteur: Gabriele Maurer

Scope: Annual reassessment of the marketing authorisation

Action: For adoption of advice to CAT and CHMP

8.1.4. Mecasermin - INCRELEX (CAP) - EMEA/H/C/000704/S/0083 (without RMP)

Applicant: Ipsen Pharma

PRAC Rapporteur: Terhi Lehtinen

Scope: Annual reassessment of the marketing authorisation

Action: For adoption of advice to CHMP

8.1.5. Tafamidis - VYNDAQEL (CAP) - EMEA/H/C/002294/S/0095 (without RMP)

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Tiphaine Vaillant

Scope: Annual reassessment of the marketing authorisation

Action: For adoption of advice to CHMP

8.2. Conditional renewals of the marketing authorisation

8.2.1. Exagamglogene autotemcel - CASGEVY (CAP) - EMEA/H/C/005763/R/0006 (without RMP)

Applicant: Vertex Pharmaceuticals (Ireland) Limited, ATMP

PRAC Rapporteur: Bianca Mulder

Scope: Conditional renewal of the marketing authorisation

Action: For adoption of advice to CAT and CHMP

8.2.2. Parathyroid hormone - NATPAR (CAP) - EMEA/H/C/003861/R/0058 (without RMP)

Applicant: Takeda Pharmaceuticals International AG Ireland Branch

PRAC Rapporteur: Rhea Fitzgerald

Scope: Conditional renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.2.3. Pemigatinib - PEMAZYRE (CAP) - EMEA/H/C/005266/R/0019 (without RMP)

Applicant: Incyte Biosciences Distribution B.V.

PRAC Rapporteur: Bianca Mulder

Scope: Conditional renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.2.4. Sparsentan - FILSPARI (CAP) - EMEA/H/C/005783/R/0004 (without RMP)

Applicant: Vifor France

PRAC Rapporteur: Martin Huber

Scope: Conditional renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3. Renewals of the marketing authorisation

8.3.1. Alpelisib - PIQRAY (CAP) - EMEA/H/C/004804/R/0028 (without RMP)

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Bianca Mulder

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.2. Budesonide, formoterol fumarate dihydrate - GORESP DIGIHALER (CAP) - EMEA/H/C/004882/R/0016 (without RMP)

Applicant: Teva Pharma B.V.

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.3. Etanercept - NEPEXTO (CAP) - EMEA/H/C/004711/R/0033 (without RMP)

Applicant: Biosimilar Collaborations Ireland Limited

PRAC Rapporteur: Monica Martinez Redondo

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.4. Glasdegib - DAURISMO (CAP) - EMEA/H/C/004878/R/0015 (without RMP)

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Bianca Mulder

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.5. Indacaterol, glycopyrronium bromide, mometasone - ENERZAIR BREEZHALER (CAP) - EMEA/H/C/005061/R/0029 (without RMP)

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Jan Neuhauser

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.6. Indacaterol, glycopyrronium bromide, mometasone - ZIMBUS BREEZHALER (CAP) - EMEA/H/C/005518/R/0025 (without RMP)

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Jan Neuhauser

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.7. Indacaterol, mometasone - ATECTURA BREEZHALER (CAP) - EMEA/H/C/005067/R/0031 (without RMP)

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Jan Neuhauser

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.8. Indacaterol, mometasone - BEMRIST BREEZHALER (CAP) - EMEA/H/C/005516/R/0026 (without RMP)

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Jan Neuhauser

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.9. Isatuximab - SARCLISA (CAP) - EMEA/H/C/004977/R/0033 (without RMP)

Applicant: Sanofi Winthrop Industrie

PRAC Rapporteur: Monica Martinez Redondo

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.10. Luspatercept - REBLOZYL (CAP) - EMEA/H/C/004444/R/0031 (without RMP)

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Jo Robays

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

9. Product related pharmacovigilance inspections

9.1. List of planned pharmacovigilance inspections

None

9.2. Ongoing or concluded pharmacovigilance inspections

Disclosure of information on results of pharmacovigilance inspections could undermine the protection of the purpose of these inspections, investigations and audits. Therefore such information is not reported in the agenda.

9.3. Others

None

10. Other safety issues for discussion requested by the CHMP or the EMA

10.1. Safety related variations of the marketing authorisation

None

10.2. Timing and message content in relation to Member States' safety announcements

None

10.3. Other requests

None

10.4. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

11. Other safety issues for discussion requested by the Member States

11.1. Safety related variations of the marketing authorisation

None

11.2. Other requests

None

12. Organisational, regulatory and methodological matters

12.1. Mandate and organisation of the PRAC

12.1.1. PRAC membership

Action: For information

12.1.2. Vote by proxy

Action: For information

12.2. Coordination with EMA Scientific Committees or CMDh-v

None

12.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

None

12.4. Cooperation within the EU regulatory network

12.4.1. Health threats and EMA Emergency Task Force (ETF) activities - update

Action: For discussion

12.5. Cooperation with International Regulators

None

12.6. Contacts of the PRAC with external parties and interaction with the Interested Parties to the Committee

None

12.7. PRAC work plan

12.7.1. PRAC work plan 2025

PRAC lead: Ulla Wändel Liminga, Liana Martirosyan

Action: For adoption

12.8. Planning and reporting

None

12.9. Pharmacovigilance audits and inspections

12.9.1. Pharmacovigilance systems and their quality systems

None

12.9.2. Pharmacovigilance inspections

None

12.9.3. Pharmacovigilance audits

None

12.10. Periodic safety update reports (PSURs) & Union reference date (EURD) list

12.10.1. Periodic safety update reports

None

12.10.2. Granularity and Periodicity Advisory Group (GPAG)

PRAC lead: Jana Lukačišinová

Action: For discussion

12.10.3. PSURs repository

None

12.10.4. Union reference date list – consultation on the draft list

Action: For adoption

12.11. Signal management

12.11.1. Signal management – feedback from Signal Management Review Technical (SMART) Working Group

PRAC lead: Martin Huber

Action: For discussion

12.11.2. Signal management – List of substances subject to worksharing

Action: For adoption

12.12. Adverse drug reactions reporting and additional reporting

12.12.1. Specific adverse drug reaction (ADR) follow-up questionnaire (FUQ) drafting group – update on the activities

PRAC lead: Tiphaine Vaillant

Action: For adoption

12.12.2. Additional monitoring

None

12.12.3. List of products under additional monitoring – consultation on the draft list

Action: For adoption

12.13. EudraVigilance database

12.13.1. Activities related to the confirmation of full functionality

None

12.14. Risk management plans and effectiveness of risk minimisations

12.14.1. Risk management systems

None

12.14.2. Tools, educational materials and effectiveness measurement of risk minimisations

None

12.15. Post-authorisation safety studies (PASS)

12.15.1. Post-authorisation Safety Studies – imposed PASS

None

12.15.2. Post-authorisation Safety Studies – non-imposed PASS

None

12.16. Community procedures

12.16.1. Referral procedures for safety reasons

None

12.17. Renewals, conditional renewals, annual reassessments

None

12.18. Risk communication and transparency

12.18.1. Public participation in pharmacovigilance

None

12.18.2. Safety communication

None

12.19. Continuous pharmacovigilance

12.19.1. Incident management

None

12.20. Impact of pharmacovigilance activities

12.20.1. Good Pharmacovigilance Practices (GVP) module XVI – Addendum on pregnancy - update

PRAC lead: Ulla Wändel Liminga

Action: For discussion

12.21. Others

12.21.1. CHMP/Member State Request for PRAC advice – guidance and updated template

PRAC lead: Ulla Wändel Liminga

Action: For discussion

13. Any other business

None

14. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

EU Referral procedures for safety reasons: Urgent EU procedures and Other EU referral procedures
(Items 2 and 3 of the PRAC agenda)

A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the European Union (EU). For further detailed information on safety related referrals please see: Referral procedures: human medicines | European Medicines Agency (europa.eu)

Signals assessment and prioritisation
(Item 4 of the PRAC agenda)

A safety signal is information on a new or incompletely documented adverse event that is potentially caused by a medicine and that warrants further investigation. Signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. The evaluation of safety signals is a routine part of pharmacovigilance and is essential to ensuring that regulatory authorities have a comprehensive knowledge of a medicine's benefits and risks.
The presence of a safety signal does not mean that a medicine has caused the reported adverse event. The adverse event could be a symptom of another illness or caused by another medicine taken by the patient.
The evaluation of safety signals is required to establish whether or not there is a causal relationship between the medicine and the reported adverse event.
The evaluation of safety signals may not necessarily conclude that the medicine caused the adverse event in question. In cases where a causal relationship is confirmed or considered likely, regulatory action may be necessary and this usually takes the form of an update of the summary of product characteristics and the package leaflet.

Risk Management Plans (RMPs)
(Item 5 of the PRAC agenda)

The RMP describes what is known and not known about the side effects of a medicine and states how these risks will be prevented or minimised in patients. It also includes plans for studies and other activities to gain more knowledge about the safety of the medicine and risk factors for developing side effects.
RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available.

Assessment of Periodic Safety Update Reports (PSURs)
(Item 6 of the PRAC agenda)

A PSUR is a report providing an evaluation of the benefit-risk balance of a medicine, which is submitted by marketing authorisation holders at defined time points following a medicine's authorisation.
PSURs summarises data on the benefits and risks of a medicine and includes the results of all studies carried out with this medicine (in the authorised and unauthorised indications).

Post-authorisation Safety Studies (PASS)
(Item 7 of the PRAC agenda)

A PASS is a study of an authorised medicinal product carried out to obtain further information on its safety, or to measure the effectiveness of risk management measures. The results of a PASS help regulatory agencies to evaluate the safety and benefit-risk profile of a medicine.

Product related pharmacovigilance inspections
(Item 9 of the PRAC agenda)

Inspections carried out by regulatory agencies to ensure that marketing authorisation holders comply with their pharmacovigilance obligations.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/